Tannin Schmidt

Associate Professor

Biomedical Engineering

Dr. Schmidt research interests in bioengineering lie within biomaterials, biomechanics, bio tribology, and biochemistry. This is motivated by my combined training in engineering science, bioengineering and biochemistry, which provide him with a unique skill set and approach to biomedical engineering research. The overarching goal of his research program is to understand the fundamental mechanisms and properties of proteoglycan 4 (PRG4), also known as lubricin (a critical lubricating protein found throughout the human body, recently discovered to also have anti-inflammatory properties), at relevant bio interfaces and biomaterials. Moreover, to then apply that fundamental knowledge to the development of PRG4-containing bio therapeutics and biomaterials. He has been an active and productive independent researcher for 9+ years, with his laboratory (previously based at the University of Calgary) being internationally recognized for its work on PRG4. The initial focus of his research program has been orthopedic in nature, studying the relevance and application of PRG4 in osteoarthritis, but expanded to other organ systems and applications in the body including but not limited to the eye (e.g. dry eye, contact lenses), heart (inhibiting post-surgical pericardial adhesions), and biomaterials in general.

Additionally, he has been successful in translating basic findings as a co-founder of Lubris BioPharma, a clinical stage startup company developing recombinant human PRG4 (rhPRG4)-based treatments for osteoarthritis, dry eye, and other diseases. Dr. Schmidt played a significant role in the development and characterization of rhPRG4, and have significant experience with the protein over the past 5 years. Collectively, his expertise and experience make him uniquely and ideally positioned to contribute to this project, specifically related to work on/with rhPRG4.